#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Fernando Aleman Guillen Email
Co-founder and CSO . Navega Therapeutics
San Diego, CA
LocationPrimary Email
How to contact Fernando Aleman Guillen
Join and see Fernando's contact info for free!Current Roles
Employees:
13Revenue:
$2MAbout
Around 1.5 billion people around the world suffer from chronic pain, with more than 100 million in the US alone. Conventional treatment for chronic pain consists mostly of opioid narcotics. However, opioids have failed us as the United States is currently undergoing an opioid epidemic. Sadly, over 120 Americans die each day of an opioid overdose. We have developed a patented, non-permanent gene therapy to target pain that is non-addictive, highly specific and long-lasting. So how does this work? We were inspired by nature: there are humans that have a mutation in their genome that feel no pain whatsoever. We have imitated this process by utilizing a novel gene therapy to target pain in a non-permanent way. In our proof of concept, we have demonstrated that the mice that received our therapy have an increased pain tolerance and lower pain levels. Importantly, mice are not numb and can continue feeling mechanical stimulation, such as touch. We believe that patients should not have to decide whether they live a life with pain, or one with the risk of addiction https://www.technologyreview.com/s/614210/the-next-trick-for-crispr-is-gene-editing-pain-away/Navega Therapeutics Address
3210 Merryfield RowSan Diego, CA